

SEQ_NO	1	Date of announcement	2024/01/30
Subject	Announcement of Important Resolutions by the Board of Directors of Our Company		
Date of events	2024/01/30	To which item it meets	paragraph 53

1.Date of occurrence of the event:2024/01/30
2.Company name:Medigen Biotechnology Corp.
3.Relationship to the Company (please enter "head office" or "subsidiaries"):head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:
To enhance the overall operational efficiency of the company, the Board of Directors has resolved to establish a strategic alliance with Taiwan Exosome Company (hereinafter referred to as the "Exosome Company"). The details of the collaboration are as follows:
1.The company plans to sell the relevant software and hardware assets (excluding real estate) of the Cell Laboratory located in Xizhi to the Exosome company, with a disposal price of NT\$220 million.
2.The company will invest in the Exosome Company 's cash capital increase through a wholly-owned investment company, by subscribing 50 million shares at NT\$2.5 per share, totaling NT\$125 million. After this investment, the company is expected to hold 29.76% in the equity of Exosome Company. In the future, Medigen Biotechnology will focus on new drug development in the field of cell therapy, with a primary emphasis on executing clinical trials to validate efficacy. The cell therapy manufacturing will be outsourced to qualified cell processing facilities. Additionally, the company recognizes the research and development capabilities as well as the long-term growth prospects of the Exosome Company. Apart from participating in equity investment, both parties will engage in business collaboration. Through the aforementioned strategic alliance and synergies, it is anticipated that there will be positive impacts on the financial and business aspects of our company.
6.Countermeasures:none
7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):none

Statement